EUVIMEDEUVIMED entdecken
Crossref

Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways

Yui Suzuki, Soichiro Usuki, Mitsuaki Nishizawa, Noriyoshi Tanaka, Yoshitomo Suhara, Ichiro Yajima

Anticancer Research · 2025

DOI: 10.21873/anticanres.17601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Yui Suzuki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Molecular and Cellular Toxicology, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute o…. Hauptthemen laut MEDLINE: Vemurafenib, Melanoma, TOR Serine-Threonine Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VemurafenibMelanomaTOR Serine-Threonine KinasesDrug Resistance, NeoplasmProto-Oncogene Proteins c-aktHumansCell Line, TumorSignal TransductionProto-Oncogene Proteins B-rafPhosphatidylinositol 3-KinasesApoptosisCell SurvivalMAP Kinase Signaling System

Stichwörter der Autor:innen

ACRAcyclic retinoidmalignant melanomavemurafenib resistance

Substanzen

VemurafenibTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMTOR protein, humanProto-Oncogene Proteins B-rafPhosphatidylinositol 3-KinasesBRAF protein, human

Autor:innen und Institutionen

  • Unit of Molecular and Cellular Toxicology, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
  • Laboratory of Organic Synthesis and Medicinal Chemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan.
  • Unit of Molecular and Cellular Toxicology, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Saitama, Japan; yajimai@shibaura-it.ac.jp.

Zitieren

APA

Suzuki, Y., Usuki, S., Nishizawa, M., Tanaka, N., Suhara, Y., & Yajima, I. (2025). Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways. Anticancer Research. https://doi.org/10.21873/anticanres.17601

Vancouver

Suzuki Y, Usuki S, Nishizawa M, Tanaka N, Suhara Y, Yajima I. Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways. Anticancer Research. 2025. doi:10.21873/anticanres.17601

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Yui and Usuki, Soichiro and Nishizawa, Mitsuaki and Tanaka, Noriyoshi and Suhara, Yoshitomo and Yajima, Ichiro},
  title = {Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17601}
}
Kostenlos starten →